Protykin (Polygonum cuspidatum extract)

Protykin is a standardized extract of Polygonum cuspidatum (Japanese knotweed) delivering concentrated trans-resveratrol, the primary bioactive stilbene responsible for its effects. It exerts anti-aging and antioxidant activity mainly by activating SIRT1 deacetylase and the Nrf2/ARE pathway, modulating gene expression linked to inflammation, oxidative stress, and cellular senescence.

Origin & History

Protykin is a branded extract from Polygonum cuspidatum (Japanese knotweed), a perennial plant native to East Asia, extracted from its roots, rhizomes, leaves, and flowers using ethanol or water extraction methods. The extract yields a polyphenolic fraction rich in stilbenes and anthraquinones, standardized to contain 10-98% resveratrol.

Historical & Cultural Context

In Traditional Chinese Medicine (TCM), Polygonum cuspidatum is known as Hu Zhang and has been used for centuries to treat dizziness, headaches, traumatic injuries, and burns. The rhizomes are traditionally valued for their anti-inflammatory and detoxification properties.

Health Benefits

• Anti-inflammatory effects: Animal studies show suppression of TLR2/NF-κB pathways and reduction in arthritis scores (preliminary evidence only)
• Antioxidant activity: Preclinical data demonstrates ROS reduction and Nrf2 activation in oxidative stress models (animal studies only)
• Hepatoprotective potential: Fructose-fed rat studies (80-160 mg/kg) showed liver protection via Keap1/Nrf2 pathways (no human data)
• Joint health support: Animal models using 65 mg/kg/day showed benefits for gouty arthritis (preclinical evidence)
• Skin-soothing properties: Cosmetic applications suggest irritation reduction benefits (traditional use basis)

How It Works

Trans-resveratrol in Protykin activates SIRT1, a NAD+-dependent deacetylase that regulates PGC-1α, p53, and NF-κB, collectively suppressing pro-inflammatory cytokine transcription and promoting mitochondrial biogenesis. It simultaneously activates the Nrf2/ARE transcription axis, upregulating endogenous antioxidant enzymes including superoxide dismutase (SOD), catalase, and heme oxygenase-1 (HO-1) to neutralize reactive oxygen species. Additionally, resveratrol inhibits TLR2-mediated NF-κB signaling and COX-2 enzyme activity, reducing prostaglandin E2 synthesis and downstream inflammatory cascades.

Scientific Research

Available evidence for Protykin is limited to preclinical studies, with no human clinical trials, RCTs, or meta-analyses identified. One review (PMC9833411) summarizes animal and in vitro anti-inflammatory effects, including polydatin administration (45 mg/kg) in mouse models and extract supplementation (4 g/kg/day for 12 weeks) in rat arthritis models.

Clinical Summary

Most evidence for Protykin derives from in vitro cell studies and rodent models; robust human clinical trials specifically using this branded extract are limited. Animal studies demonstrate reductions in arthritis severity scores and hepatic oxidative stress markers following oral resveratrol administration at doses of 20–100 mg/kg. A small number of human pharmacokinetic trials confirm that trans-resveratrol from Polygonum cuspidatum is bioavailable, though oral bioavailability remains low (~1%) due to rapid glucuronidation and sulfation. The overall evidence base is preliminary; Protykin's health claims should be considered promising but not yet established by large-scale randomized controlled trials.

Nutritional Profile

Protykin is a standardized extract of Polygonum cuspidatum (Japanese knotweed) root, not consumed as a whole food, so macronutrient values (protein, fat, carbohydrate, fiber) are negligible at typical supplement doses. Key bioactive compounds: • Trans-resveratrol: Protykin is standardized to contain approximately 20% trans-resveratrol (roughly 200 mg per gram of extract), which is the primary active stilbenoid and the main reason for commercial interest; bioavailability of oral trans-resveratrol is low (~1–5% reaches systemic circulation unchanged) due to rapid Phase II metabolism (glucuronidation and sulfation in intestinal epithelium and liver), though metabolites (resveratrol-3-O-sulfate, resveratrol-3-O-glucuronide) may retain partial biological activity. • Emodin: Present at approximately 1–5% of extract weight; an anthraquinone with laxative, anti-inflammatory, and hepatoprotective properties; oral bioavailability is low (~7–10%) due to extensive glucuronidation. • Polydatin (piceid/resveratrol-3-O-β-D-glucoside): Typically 5–15% of extract; a glycosylated form of resveratrol with modestly higher water solubility and potentially improved intestinal absorption compared to free resveratrol, as it may be absorbed via SGLT1 glucose transporters before hydrolysis to free resveratrol by gut microbiota. • Proanthocyanidins/catechins: Minor amounts (~1–3%), contributing to overall antioxidant capacity (ORAC values reported in the range of 3,000–5,000 µmol TE/g extract). • Chrysophanol and physcion: Trace anthraquinone derivatives (<1%), contributing mild additional anti-inflammatory effects. • Minerals: Trace amounts of calcium, potassium, iron, and zinc derived from the root matrix, but quantities are nutritionally insignificant at supplemental doses (typically 100–500 mg extract/day). • No significant vitamin content. • No meaningful caloric contribution. Bioavailability notes: Co-administration with piperine (BioPerine) or lipid-based delivery systems has been reported in preclinical models to enhance resveratrol bioavailability by 2–5-fold via inhibition of glucuronidation. The presence of polydatin in the whole extract may provide a sustained-release reservoir of resveratrol through gradual microbial hydrolysis in the colon.

Preparation & Dosage

No clinically studied human dosages are available. Animal studies used polydatin at 7.5-50 mg/kg and extract at 65-4000 mg/kg daily, with commercial extracts standardized to 10-98% resveratrol content. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Curcumin, Green Tea Extract, Boswellia, NAD+ precursors

Safety & Interactions

Protykin is generally well tolerated at typical supplemental doses of 200–500 mg/day of standardized trans-resveratrol, with gastrointestinal discomfort (nausea, diarrhea) reported at higher doses exceeding 1,000 mg/day. Trans-resveratrol inhibits CYP3A4, CYP2C9, and CYP2D6 enzymes, creating a clinically relevant risk of elevated plasma concentrations of anticoagulants (warfarin), statins, and immunosuppressants such as cyclosporine. It may also potentiate the effects of antiplatelet drugs and NSAIDs, increasing bleeding risk, and should be discontinued at least two weeks before surgery. Safety in pregnancy and lactation has not been established in humans, and use is not recommended in these populations.